Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
By J. Ridgway, Gu Zhang, Yan Wu, S. Stawicki, Wei-Ching Liang, Yvan H. Chanthery, J. Kowalski, R. Watts, C. Callahan, I. Kasman and 7 more. Nature, 2006
1,061 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/fdaac98559700cca1c1871446024437573fa35c6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Rakesh K. Jain
- N. Ferrara
- D. Duda
- Alicia S. Chung
- Jay S. Loeffler
- E. di Tomaso
- Tracy T. Batchelor
- A. Sorensen
Citations in the corpus
- Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways (2011, background): “Reported complications of continuous antibody-mediated inhibition of Notch include the development of angiomas and neovascular tuft formation”
- Targeting the tumour vasculature: insights from physiological angiogenesis (2010, background): “The role of DLL4–Notch signalling during physiological angiogenesis is to limit excessive angiogenesis as a negative feedback mechanism and to promote the formation of a functional, mature vasculatur”
- Angiogenesis in brain tumours (2007, background): “Neutralizing DLL4 with a DLL4-selective antibody rendered endothelial cells hyperproliferative and caused defective cell-fate specification or cell differentiation both in vitro and in vivo , inhibiting tumour growth in several tumour model”
- The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism (2009, background): “Notch signaling has emerged as a specific therapeutic target for T cell acute lymphoblastic leukemia (Weng et al., 2004) and colon cancer (van Es et al., 2005), as well as a potential target in the effort to curb tumor angiogenesis (Noguera-Troise et al., 2006; Ridgway et al., 2006).”
- Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “Recently, antibodies that are selective for the Notch ligand Delta-like 4 ( DLL4 ) were shown to inhibit tumour growth by deregulating angiogenesis without much of the toxicity related to γ-secretase inhibition in animal model”
- The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. (2009, neutral): “, 2007; Siekmann and Lawson, 2007), or in experimental tumors (Li et al., 2007; Noguera-Troise et al., 2006; Ridgway et al., 2006).”